Bodén Robert, Bexelius Tomas S, Mattsson Fredrik, Lagergren Jesper, Lindblad Mats, Ljung Rickard
Department of Neuroscience, Unit of Psychiatry, Uppsala University, Uppsala, Sweden.
BMJ Open. 2012 May 11;2(3). doi: 10.1136/bmjopen-2012-000914. Print 2012.
To evaluate the suggested association between antidopaminergic drugs and acute pancreatitis.
A large population-based nested case-control study.
Swedish nationwide study from 2006 to 2008.
The Patient Register was used to identify 6161 cases of acute pancreatitis. The 61 637 control subjects were randomly selected from the Register of the Total Population by frequency-based density sampling, matched for age, sex and calendar year.
Exposure data were extracted from the Prescribed Drug Register. Antidopaminergic drugs were grouped into antiemetic/anxiolytic and other antipsychotics. Current use of antidopaminergic drugs was defined as filling a prescription 1-114 days before index date, while previous use was 115 days to 3.5 years before index date.
Cases were defined as being diagnosed as having acute pancreatitis. ORs and 95% CIs were calculated using unconditional logistic regression.
The unadjusted OR indicated an increased risk of acute pancreatitis among current users of antiemetic/anxiolytics (OR 1.9, 95% CI 1.4 to 2.6), but not in the multivariable model adjusting for alcohol-related comorbidity, chronic obstructive lung disease, ischaemic heart disease, obesity, diabetes, opioid use, gallstone disease, educational level, marital status and number of concomitant medications (OR 0.9, 95% CI 0.6 to 1.2). Similarly, among current users of other antipsychotics, the unadjusted OR was 1.4 (95% CI 1.1 to 1.6), while the adjusted OR was 0.8 (95% CI 0.6 to 0.9). Results regarding previous use of antidopaminergic drugs followed a similar risk pattern as for current use.
The lack of association between antidopaminergic drugs and acute pancreatitis after adjustment for confounding factors in this study suggests that the previously reported positive associations might be explained by confounding.
评估抗多巴胺能药物与急性胰腺炎之间的假定关联。
一项基于人群的大型巢式病例对照研究。
2006年至2008年的瑞典全国性研究。
使用患者登记册确定6161例急性胰腺炎病例。61637名对照对象通过基于频率的密度抽样从总人口登记册中随机选取,并按年龄、性别和日历年份进行匹配。
从处方药登记册中提取暴露数据。抗多巴胺能药物分为抗呕吐/抗焦虑药物和其他抗精神病药物。当前使用抗多巴胺能药物定义为在索引日期前1 - 114天开具处方,而既往使用则为索引日期前115天至3.5年。
病例定义为被诊断患有急性胰腺炎。使用无条件逻辑回归计算比值比(OR)和95%可信区间(CI)。
未调整的OR表明,当前使用抗呕吐/抗焦虑药物的人群中急性胰腺炎风险增加(OR 1.9,95% CI 1.4至2.6),但在针对酒精相关合并症、慢性阻塞性肺疾病、缺血性心脏病、肥胖、糖尿病、阿片类药物使用、胆结石疾病、教育水平、婚姻状况和合并用药数量进行调整的多变量模型中并非如此(OR 0.9,95% CI 0.6至1.2)。同样,在当前使用其他抗精神病药物的人群中,未调整的OR为1.4(95% CI 1.1至1.6),而调整后的OR为0.8(95% CI 0.6至0.9)。关于既往使用抗多巴胺能药物的结果与当前使用呈现相似的风险模式。
本研究在调整混杂因素后,抗多巴胺能药物与急性胰腺炎之间缺乏关联,这表明先前报道的阳性关联可能是由混杂因素所致。